# Hybrid treat-and-repair strategy for large patent ductus arteriosus: a proof-of-concept case report

**Authors:** Naoki Tsuboya, Yoshihide Mitani, Hiroyuki Ohashi, Hirofumi Sawada, Masahiro Hirayama

PMC · DOI: 10.1093/ehjcr/ytae354 · European Heart Journal. Case Reports · 2024-07-23

## TL;DR

A new hybrid strategy combining surgery and medication successfully treated a large patent ductus arteriosus in a child with pulmonary hypertension.

## Contribution

This is the first proof-of-concept case report demonstrating a hybrid treat-and-repair strategy for large PDA with pulmonary hypertension.

## Key findings

- Hybrid strategy reduced pulmonary artery resistance and improved hemodynamics in a 10-year-old patient with large PDA and PAH.
- Transcatheter closure was safely performed after successful pulmonary vasodilator therapy and surgical duct banding.
- Mid-term follow-up showed favorable outcomes and improved exercise capacity.

## Abstract

In cases of atrial septal defect with pulmonary arterial hypertension (PAH), a treat-and-repair strategy that adopts pulmonary vasodilator therapy and subsequent defect closure is postulated to be effective. However, this strategy has not been applied to the large patent ductus arteriosus (PDA) with PAH.

A 10-year-old girl with trisomy 21 was referred to our hospital for the treatment of a large PDA with PAH. Cardiac catheterization and angiography revealed a type C tubular PDA with a minimal diameter of 8.1 mm, an increase in mean pulmonary artery pressure (mPAP) of 60 mmHg, a ratio of pulmonary to systemic blood flow (Qp/Qs) of 2.7, and pulmonary artery resistance (Rp) of 7.1 U/m2. Because she was categorized in the grey zone for operability, we adopted a hybrid treat-and-repair strategy in which palliative surgical duct banding was performed before pulmonary vasodilator therapy to prevent excessive pulmonary blood flow and was followed by transcatheter closure of the PDA. Postoperatively, we confirmed the flow-restricted duct with a minimal diameter of 3.3 mm, decreased Qp/Qs 1.38, high mPAP 40 mmHg, and Rp 7.3 U/m2. Six months after treatment with macitentan and tadalafil, we confirmed a decrease in Rp 4.1 U/m2 as well as low Qp/Qs 1.12, which was low enough for the duct occlusion. The transcatheter occlusion of the surgically created type A conical duct was easily and safely performed. In the mid-term follow-up, favourable haemodynamics and improved exercise were confirmed.

This is the first proof-of-concept case report to show the successful hybrid treat-and-repair strategy for large PDA, which warrants further investigation.

## Linked entities

- **Chemicals:** macitentan (PubChem CID 16004692), tadalafil (PubChem CID 110635)
- **Diseases:** pulmonary arterial hypertension (MONDO:0015924), patent ductus arteriosus (MONDO:0011827), atrial septal defect (MONDO:0006664)

## Full-text entities

- **Diseases:** PAH (MESH:D000081029), PDA (MESH:D004374), duct occlusion (MESH:D001157), trisomy 21 (MESH:D004314), atrial septal defect (MESH:D006344)
- **Chemicals:** pulmonary vasodilator (-), tadalafil (MESH:D000068581), macitentan (MESH:C533860)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11299020/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11299020/full.md

## References

6 references — full list in the complete paper: https://tomesphere.com/paper/PMC11299020/full.md

---
Source: https://tomesphere.com/paper/PMC11299020